ESR1 and breast cancer: The triple-positive subgroup (HER2+/ER+/PR+) with BM shows the best prognosis among patients with BM [58,119,120], compared to HER2 positive, hormone receptor-negative and HER2 negative BC [58], even though mostly the treatment is initially based on HER2 based medications.